Zimmer Biomet Holdings found using ticker (ZBH) have now 20 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The target price ranges between 145 and 114 with a mean TP of 127. Now with the previous closing price of 114.52 this would imply there is a potential upside of 10.9%. The 50 day MA is 108.96 while the 200 day moving average is 118.84. The company has a market capitalisation of $23,758m. Visit the company website at: https://www.zimmerbiomet.com
The potential market cap would be $26,347m based on the market concensus.
Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings and changed its name to Zimmer Biomet Holdings in June 2015. Zimmer Biomet Holdings was founded in 1927 and is headquartered in Warsaw, Indiana.
